期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

影响吸入粉雾剂分散性能的制剂因素 被引量：5

Pharmaceutical Influence Factors on Dispersibility of Dry Powder Inhalation
下载PDF
导出
摘要 综述了影响吸入粉雾剂分散性能的主要制剂因素,简要介绍了近年来提高粉雾剂性能的制剂方法的研究进展和有关研发和评价的新技术。 The main pharmaceutical influence factors on the dispersibility of dry powder inhalation are reviewed. The recent advances in formulation and application of new technology to R＆D as well as evaluation are briefly introduced.
作者 江荣高 王立青 王春龙 潘卫三
机构地区 沈阳药科大学药学院 天津药物研究院
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2006年第1期50-53,共4页 Chinese Journal of Pharmaceuticals
关键词 粉雾剂 分散性 吸入用细粉 载体 第三组分 综述 dry powder inhalation dispersibility respirable fine particles carrier ternary component review
分类号 R944.9 [医药卫生—药剂学]
  • 相关文献

参考文献30

  • 1[1]Morita T,Horikiri Y,Yamahara H,et al.Formation and isolation of spherical fine protein microparticles through lyophilization of protein-poly (ethylene glycol) aqueous mixture[J].Pharm Res,2000,17(11):1367-1373.
  • 2[2]Maa YF,Ameri M,Shu C,et al.Influenza vaccine powder formulation development:spray-freeze-drying and stability evaluation [J].J Pharm Sci,2004,93 (7):1912-1923.
  • 3[3]Cheng YS,Yazzie D,Gao J,et al.Particle characteristics and lung deposition patterns in a human airway replica of a dry powder formulation of polylactic acid produced using supercritical fluid technology [J].J Aerosol Med,2003,16(1):65-73.
  • 4[4]E1-Baseir MM,Kellaway IW.Poly (L-lactic acid) microspheres for pulmonary drug delivery:release kinetics and aerosolization studies [J].Int J Pharm,1998,175 (2):135-146.
  • 5[5]Young PM,Price R,Tobyn MJ,et al.Investigation into the effect of humidity on drug-drug interactions using the atomic force microscope [J].J Pharm Sci,2003,92 (4):815-822.
  • 6[6]Dunbar C,Scheuch G,Sommerer K,et al.In vitro and in vivodose delivery characteristics of large porous particles for inhalation[J],lnt J Pharm,2002,245 (1-2):179-189.
  • 7[7]Newhouse MT,Hirst PH,Duddu SP,et al.Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers [J].Chest,2003,124 (1):360-366.
  • 8[8]Kawashima Y,Serigano T,Hino T,et al.Design of inhalation dry powder of pranlukast hydrate to improve dispersibility by the surface modification with light anhydrous silicic acid (AEROSIL 200) [J].Int J Pharm,1998,173 (1,2):243-251.
  • 9[9]Ikegami K,Kawashima Y,Takeuchi H,et al.A new agglomerated KSR-592 β-form crystal system for dry powder inhalation formulation to improve inhalation performance in vitro and in vivo [J ].J Controlled Release,2003,88 (1):23-33.
  • 10[10]Steckel H,Mueller BW.In vitro evaluation of dry powder inhalers Ⅱ:influence of carrier particle size and concentration on in vitro deposition [J].Int J Pharm,1997,154 (1):31-37.

同被引文献94

引证文献5

二级引证文献15

中国医药工业杂志
2006年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部